As the COVID-19 pandemic continues to affect the world’s economies, some consumer healthcare categories are faring better than others. Timely updates from our KlinePULSE Consumer Healthcare Industry Trends: U.S. Annual Subscriptions Service provide research findings on noteworthy category developments.
Earlier this month, Sanofi announced a new strategic vision for its Consumer Healthcare division. The new head of the division, Julie Van Ongevalle, shared that the company will focus on core brands and categories while pursuing first-in-class Rx-to-OTC switches in the ED and flu categories in the United States. Key components to future growth of Sanofi’s OTC business in the United States are novel Rx-to-OTC switches. The company is entrenched in its work to develop nonprescription versions of Cialis for erectile dysfunction and Tamiflu influenza medication in the States. As of December 2020, Sanofi has more than 16 clinical studies either complete or underway to support applications for OTC marketing of these two medications. Actual–use trials to understand how consumers behave and interact with these medicines will be key factors in the success of the switches. These brands have the potential to be blockbusters, as there are currently no medications for either condition available without a prescription in the United States. Detailed analyses of both of these medications and the likelihood and timing of approval and sales forecasts are included in Kline’s Rx-to-OTC Switch Forecasts study. Continue reading
As 2020 concludes, we are reflecting on the priority of health and safety, and how drastically different our everyday lives are compared to just eight months ago. We have seen major shifts toward the importance of immunity, with less emphasis on treatment of symptoms and more focus on prevention. We have a new perspective on the evolving role consumer healthcare products play in keeping us healthy. To help you put these major trends into perspective, below is a summary of our market studies and whitepapers that were published throughout the year. Continue reading
Restful sleep remains an elusive goal for many adults and therefore, strong gains for sleep aids, including OTC sleep aids, natural sleep products, pain+sleep combination products, and sleep devices are forecast over the next five years by Kline’s Sleep Aids: U.S. Market Analysis and Opportunities study. Estimates range from 30%-40% of American adults experience symptoms of insomnia and 40 million are affected by chronic long-term sleep disorders.Continue reading
OTC indies, companies that are driving significant growth are either early adopters of a particular health trend such as Suja Life or Health-Ade Kombucha or companies that are breathing new life into iconic brands such as Infirst, Focus Consumer Healthcare, and Foundation Consumer Healthcare. These brands, collectively, generated almost $1.8 billion in manufacturer-level sales in 2018, representing more than 13% in year-over-year growth, finds the just-published OTC Indies: U.S. Analysis of Independent OTC Companies study by international market research and management consulting firm Kline.Continue reading